This strategic acquisition will enhance SGD Pharma's capabilities and expand its market presence in Europe.
Alphial Srl is a tubular glass converting company that manufactures ampoules, vials and ready-to-use (RTU) products.
The company employs more than 220 people at four manufacturing sites in Italy.
This acquisition will constitute another step in the implementation of SGD's strategy to reinforce its tubular glass manufacturing presence globally.
Two years ago, SGD Pharma announced a joint venture with Corning to set a new tubing facility near its Vemula facility in India.
The objective was to secure its supply chain, reduce its carbon footprint and master its quality. This new site is about to be operational and the first tube to be produced.
Alphial Srl is another important step and will ideally complement the company's existing operations in Europe and in India.
"This acquisition aligns with our commitment to getting closer and delivering exceptional value to our customers. We are excited to welcome Alphial Srl to the SGD Pharma family," said Olivier Rousseau, CEO of SGD Pharma.
"This acquisition represents a significant milestone in our growth strategy and will enable us to better serve our clients with an expanded portfolio of services and solutions."
“We have been investing heavily in the development of tubular glass and RTUs in recent years,” said Fabio Invernizzi, General Manager of the West Business Unit.
“Together with the SGD Pharma team, I’m truly excited to engage with the Alphial team to make this happen.”
Valerio Marchi, CEO of Alphial Srl, added: “We are really pleased to join the SGD Pharma Group. SGD Pharma will help Alphial grow and improve the quality of its offering and of its industrial performance.”
"We are committed to ensuring a smooth transition for all stakeholders and look forward to the opportunities this acquisition will bring; we are confident that it will drive long-term growth and success for both companies."